🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Windlas Biotech Limited WINDLAS NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://windlas.com
Company Profile ↓
₹850.55
-5.82% 1Y
Mkt Cap₹1,795.19 Cr
P/E29.46
P/B3.35
Div. Yield0.76%
52W High₹1,070.80
52W Low₹705.75
Book Value₹275.20
EPS (TTM)₹28.87

Company Overview

Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophilized vials, and ampoules. In addition, the company offers generic drugs for respiratory, anti-diabetic, gastroenterology, cardiovascular and multivitamin, neuro anti-psychotic, diabetic care, nutraceuticals, nutritional supplement, urology, pain management, and injectable therapies. It also exports generic medicines, health supplements, and custom-branded formulations. Windlas Biotech Limited was incorporated in 2001 and is headquartered in Dehradun, India.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 15.7%.

Consistent Profit Growth

Net profit has compounded at 16.0% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 20.7% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 29.5, below the sector median of 40.0.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.06.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹897.70 Cr (+18.9% YoY); net profit ₹66.46 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +18.9%, earnings +8.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR 20.7%, profit CAGR 16.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:20.69%
1 Year:18.88%

Compounded Profit Growth

5 Years:15.95%
1 Year:8.95%

Stock Price Performance

1 Year:-5.82%
6 Months:+11.88%
3 Months:-1.82%
1 Month:+3.83%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 40% of range
₹705.75 ₹1,070.80
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • Golden Cross3d ago
  • RSI (14)54.31 · Neutral
Price Performance
1M+3.83%
3M-1.82%
6M+11.88%
1Y-5.82%
Valuation vs Sector

P/E of 29.46 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 20.7% over 5 years.
  • Profit CAGR of 16.0% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
29.46
Industry PE
39.97
Forward P/E est.
27.04
PEG Ratio
-
Book Value
₹275.20
Price to Book
3.35
P/S
1.95
EV/EBITDA
15.04
Dividend Yield
0.76%

Growth (CAGR)

Revenue 5Y
20.69%
Profit 5Y
15.95%
Revenue (YoY)
18.88%
Earnings (YoY)
8.95%

Profitability & Returns

ROCE
15.65%
ROE
11.44%
ROA
7.32%
Profit Margin
7.40%
Op Margin
8.27%
Gross Margin
37.93%
EPS (Latest Qtr)
₹7.49
EPS (TTM)
₹28.87

Balance Sheet & Liquidity

Debt/Equity
0.06
Quick Ratio
1.76
Current Ratio
1.95
Debt
₹35.24 Cr
Total Assets
₹907.35 Cr
Current Assets
₹626.85 Cr
Working Capital
₹305.92 Cr

Ownership

Promoter Holding
65.75%
Chg in Prom Hold
-1.56%
FII / Inst Holding
9.56%
Chg in FII Hold
0.00%

Financial Snapshot

Enterprise Value
₹1,795.19 Cr
Total Revenue (TTM)
₹897.70 Cr
EBITDA
₹122.55 Cr
Free Cash Flow
₹37.27 Cr
Operating Cash Flow
₹104.93 Cr
Shares Outstanding
₹2.11 Cr
Gross Margin
37.93%
Payout Ratio
18.62%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 WINDLAS Windlas Biotech Limited NSEPHARMA 850.55 29.46 ₹1,795.19 Cr 0.76% 15.65% 11.44% 20.69% 15.95%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 141.00 Cr145.00 Cr153.00 Cr162.00 Cr171.00 Cr175.00 Cr187.00 Cr195.00 Cr202.71 Cr210.09 Cr222.40 Cr233.10 Cr238.50 Cr
Cost of Revenue --------125.19 Cr129.73 Cr136.95 Cr143.50 Cr147.05 Cr
Gross Profit --------77.51 Cr80.36 Cr85.45 Cr89.60 Cr91.45 Cr
Operating Expenses 124.00 Cr128.00 Cr134.00 Cr142.00 Cr149.00 Cr154.00 Cr164.00 Cr170.00 Cr60.30 Cr61.28 Cr64.49 Cr72.92 Cr74.16 Cr
Operating Income 12.00 Cr14.00 Cr16.00 Cr17.00 Cr18.00 Cr15.00 Cr17.00 Cr18.00 Cr17.21 Cr19.08 Cr20.96 Cr16.68 Cr17.29 Cr
EBITDA 16.00 Cr17.00 Cr19.00 Cr20.00 Cr22.00 Cr21.00 Cr23.00 Cr25.00 Cr30.48 Cr31.76 Cr32.20 Cr28.95 Cr29.64 Cr
Interest Expense 0000001.00 Cr1.00 Cr1.33 Cr1.06 Cr1.02 Cr1.28 Cr1.48 Cr
Pretax Income 15.00 Cr16.00 Cr18.00 Cr20.00 Cr23.00 Cr18.00 Cr20.00 Cr20.00 Cr20.82 Cr23.26 Cr23.59 Cr19.97 Cr20.16 Cr
Tax Provision 3.60 Cr4.16 Cr4.14 Cr4.80 Cr5.75 Cr4.68 Cr4.60 Cr4.60 Cr4.54 Cr5.59 Cr5.79 Cr4.97 Cr4.17 Cr
Net Income 11.00 Cr12.00 Cr14.00 Cr15.00 Cr17.00 Cr13.00 Cr16.00 Cr16.00 Cr16.28 Cr17.66 Cr17.80 Cr15.00 Cr15.99 Cr
Diluted EPS 5.385.806.757.268.176.457.497.457.698.348.407.057.49

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 352.00 Cr307.00 Cr329.00 Cr428.00 Cr-510.58 Cr628.88 Cr755.13 Cr897.70 Cr
Cost of Revenue -----325.45 Cr396.18 Cr471.86 Cr557.23 Cr
Gross Profit -----185.13 Cr232.71 Cr283.27 Cr340.46 Cr
Operating Expenses 313.00 Cr270.00 Cr295.00 Cr373.00 Cr-137.21 Cr167.98 Cr216.66 Cr266.23 Cr
Operating Income 22.00 Cr27.00 Cr25.00 Cr42.00 Cr-47.92 Cr64.73 Cr66.61 Cr74.23 Cr
EBITDA 39.00 Cr38.00 Cr34.00 Cr55.00 Cr-70.19 Cr91.64 Cr112.12 Cr122.55 Cr
Interest Expense 6.00 Cr5.00 Cr3.00 Cr1.00 Cr-78.80 L1.10 Cr4.38 Cr4.83 Cr
Pretax Income 20.00 Cr76.00 Cr25.00 Cr22.00 Cr-57.04 Cr77.09 Cr79.76 Cr86.98 Cr
Tax Provision 8.80 Cr12.16 Cr8.50 Cr6.16 Cr-14.41 Cr18.90 Cr18.76 Cr20.52 Cr
Net Income 11.00 Cr64.00 Cr16.00 Cr16.00 Cr-42.63 Cr58.19 Cr60.99 Cr66.46 Cr
Diluted EPS 20.0499.5525.2824.6918.5819.7027.8828.87-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 290.00 Cr298.00 Cr338.00 Cr296.00 Cr-528.98 Cr626.21 Cr760.45 Cr907.35 Cr
Current Assets -----353.54 Cr431.29 Cr525.43 Cr626.85 Cr
Cash & Equivalents -----3.69 Cr5.29 Cr42.40 L53.50 L
Inventory -----74.74 Cr62.19 Cr81.38 Cr61.82 Cr
Receivables -----116.86 Cr136.28 Cr166.86 Cr227.40 Cr
Total Liabilities -----126.70 Cr176.27 Cr254.68 Cr326.51 Cr
Current Liabilities -----121.24 Cr171.75 Cr249.44 Cr320.93 Cr
Long Term Debt ----44.40 L10.90 L00-
Total Debt 57.00 Cr32.00 Cr29.00 Cr32.00 Cr-4.99 Cr3.64 Cr32.60 Cr35.24 Cr
Total Equity 125.00 Cr193.00 Cr209.00 Cr199.00 Cr-402.27 Cr449.94 Cr505.77 Cr580.84 Cr
Shares Outstanding -----2.18 Cr2.08 Cr2.10 Cr2.11 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 35.00 Cr19.00 Cr25.00 Cr11.00 Cr-60.97 Cr108.96 Cr68.19 Cr104.93 Cr
Investing Cash Flow -11.00 Cr-7.00 Cr-14.00 Cr-20.00 Cr--14.11 Cr-92.07 Cr-74.06 Cr-91.79 Cr
Financing Cash Flow -26.00 Cr-6.00 Cr-5.00 Cr1.00 Cr--43.74 Cr-15.29 Cr1.01 Cr-13.03 Cr
Capital Expenditure -25.00 Cr-9.00 Cr-15.00 Cr-5.00 Cr--70.89 Cr-37.68 Cr-52.19 Cr-67.66 Cr
Free Cash Flow 10.00 Cr10.00 Cr10.00 Cr6.00 Cr--9.93 Cr71.28 Cr15.99 Cr37.27 Cr
Net Change in Cash -2.00 Cr6.00 Cr5.00 Cr-8.00 Cr-3.12 Cr1.60 Cr-4.86 Cr11.10 L

Ratios (Annual)

Figures in %.

Metric Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -----36.3%37.0%37.5%37.9%
Operating Margin % 6.2%8.8%7.6%9.8%-9.4%10.3%8.8%8.3%
Net Margin % 3.1%20.8%4.9%3.7%-8.3%9.3%8.1%7.4%
ROE % 8.8%33.2%7.7%8.0%-10.6%12.9%12.1%11.4%
ROCE % -----11.8%14.2%13.0%12.7%

Shareholding Pattern

Insiders
65.75%
Institutions
9.56%
Public Float
27.92%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for WINDLAS

Google News Sun, 12 Jul 2026

Be Sure To Check Out Windlas Biotech Limited (NSE:WINDLAS) Before It Goes Ex-Dividend - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxOQW55dUVNbEd0VUVlRjVvTkFLZUxuQXA3cEtndjFrNlpiNVNWS1Y1TF9TZ3JkN2JPSTRVS1hSdEJaZjZuME55S2JHLWxNV01SSTk4TGNGSkhyM0lNQTF0eE5ZTDRSLXkxYkRqaFFaWmVNTHBFNzlnTFd4NGhsQ0RTSW9lMDFzMlk3b2lVel…

Google News Sun, 12 Jul 2026

Windlas Biotech hosting analyst meet on 14 Jul 2026 - scanx.trade

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxOTzlCTDhHbVBmLXVDa3A3dGlONmd0ajRiMzBRNW43YlVWSlkzX3JMRU1saXpGU2tiMzNHS20wQ1RDYnBCNHJrNDhqbjBZRm5XaWFxbHR6NHlkQWx6Z3Jkb2dpdldtQTA3QlBMTlVsbU1KWFB4RHBIdDFGbUVleXpsd2tRYldHSXBXeHpTNU…

Google News Wed, 15 Apr 2026

Share buybacks this month: Wipro, Aurobindo Pharma, 2 other stocks to watch out for - The Economic Times

<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxQa0d1S1c1a0JHeUxNTWtvSGdJa2RDUkpVaS1Gek42NXVRQTU2cVN4OFJuXzZGRW9ObkdHU29PWHNrY0VxT0R4T2FBMHoyT3dqdXhGRjc1RkZYQUk3ZS1XN0RCWFlUVXlIUlM4VjBOb18wUWQwQzE5aG9XeF93aFVzZ29EeWR5QnIza1h4VX…

Google News hu, 09 Jul 2026

Solid Earnings May Not Tell The Whole Story For Windlas Biotech (NSE:WINDLAS) - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxQSVdYMTBEeXJvU3BnTVRHQV80TjRSZTVreFRZV2dkbmh5MEZmeWlmd3RaR0xzb1F2RGdUTmVfWlVEejJkQjdZME9hcE9NRWNlemV0emlVcHVlLU9oQjVRT2V4QzhVaU5yMmtpZ0RiN1BOaU5MVzRtNGdVVGY0YmVndWROWFZOU2p3NnVYTH…

Google News Fri, 17 Apr 2026

Board of Windlas Biotech approves buyback of shares of Rs 47 cr - Business Standard

<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxQaWpKbVlrc19ZRmpYMW92X2NIYUtHWkJaT2RYYXJYeGszeUJuekZxNk5VZ1BCT016T2JqdGVic3ZBZjM5TnJ0QUpjWVVTTnRESXZJSEp6d0MtcDVPclRRd3IwRk5xWTV6SXYwMmowNDVvbzZTd2VTTWdqdDFjc09heDc2VGlqcTRMQVVFdz…

Google News Sat, 03 Jan 2026

Windlas Biotech Ltd. Share Price Today - Windlas Biotech Ltd. Stock Price Live NSE/BSE - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxOdXhqRkxJc3ZyeVkzSjdXbm9zSGlzNVY5bmc5S2t4UVEtNnNqclgzZmY0UWl1Xy1HOXBVTl9nVjFLcEw3am1oMjRac1VlaXJTeHFXWG1odDg3SXlwaGZtaUYzQlJCaUVxUy1BQzVWNVpKTTRWX2VpTG5CUzBlOG80NTZn?oc=5" target=…

WINDLAS — Frequently Asked Questions

What is the current share price of Windlas Biotech Limited (WINDLAS)?

As of 2026-07-15 09:52 IST, Windlas Biotech Limited (WINDLAS) trades at ₹850.55 on NSE. Its 52-week range is ₹705.75 to ₹1,070.80.

What is the market capitalisation of WINDLAS?

Windlas Biotech Limited (WINDLAS) has a market capitalisation of ₹1,795.19 Cr on NSE.

What is the P/E ratio of WINDLAS?

WINDLAS trades at a trailing price-to-earnings (P/E) ratio of 29.46. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 3.35.

Does WINDLAS pay a dividend?

Windlas Biotech Limited (WINDLAS) currently offers a dividend yield of 0.76%.

What is the return on equity (ROE) of WINDLAS?

WINDLAS has a return on equity (ROE) of 11.44%. Its return on capital employed (ROCE) is 15.65%.

Is WINDLAS a good stock to buy?

This page provides a data-driven analysis of Windlas Biotech Limited (WINDLAS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space